Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aneurysmal Subarachnoid Hemorrhage
Conditions
Aneurysmal Subarachnoid Hemorrhage
Trial Timeline
Jan 10, 2005 → Mar 30, 2006
NCT ID
NCT00111085About Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo
Clazosentan 1 mg/h + Clazosentan 5 mg/h + Clazosentan 15 mg/h + Placebo is a phase 2 stage product being developed by Idorsia for Aneurysmal Subarachnoid Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00111085. Target conditions include Aneurysmal Subarachnoid Hemorrhage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00111085 | Phase 2 | Completed |
Competing Products
8 competing products in Aneurysmal Subarachnoid Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erythropoietin beta | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Phase 2 | 51 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan | Idorsia | Phase 2 | 47 |
| Clazosentan 5 m/h + Clazosentan 15 mg/h + Placebo | Idorsia | Phase 3 | 72 |
| Clazosentan + Placebo | Idorsia | Phase 3 | 72 |
| GTX-104 + Nimodipine Capsules | Grace Therapeutics | Phase 1 | 25 |
| GTX-104 + Nimotop 30 MG Oral Capsule | Grace Therapeutics | Phase 3 | 69 |